AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03137134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib in a coated microsphere formulation
Study NCT03137134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor, esomeprazole
Study NCT03771482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quiztime modules
Description: Text Messaging or Email system
Study NCT01741753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Orally, every morning
Study NCT01741753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Orally, 1000 mg, every morning
Study NCT01741753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally, 5 mg, every morning
Study NCT02509533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C.®
Description: Patients received V.A.C.® Therapy (KCI medical) after a transplants of leg ulcers.
Study NCT02509533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dressing
Description: Patients received usual dressing method (compresses) after a transplants of leg ulcers
Study NCT01797822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial tear
Study NCT03058679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks
Study NCT03058679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks
Study NCT02136277 — intervention group
Intervention type: DRUG
Intervention: Hartmann's solution
Description: Administered in 250ml boluses, until cardiac output has been optimised.
Study NCT03155607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: Patient will utilize a virtual reality device during wound care.
Study NCT00982358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Study NCT00982358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01737034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention by varying GI diets
Description: The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.
Study NCT01113541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone HCL (oral)
Description: Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
Study NCT04158453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AUT00201
Description: Oral dose of AUT00201
Study NCT04158453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose of placebo
Study NCT01798238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513
Description: form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
Study NCT01798238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
Study NCT02547025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole+3 antibiotics
Description: (rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
Study NCT02547025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole+bismuth+2 antibiotics
Description: (rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
Study NCT02547025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole+amox+tetr+levo
Description: (rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
Study NCT02821689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. The maximum dose was maintained throughout the study in patients who tolerated it.
Study NCT00996619 — intervention group
Intervention type: PROCEDURE
Intervention: An optical fiber, inside the work channel of an endoscope, is added to the endoscopic examination
Description: An optical fiber, inside the work channel of an endoscope, connected to a spectroscope, enables measuring the spectrum of objects seen by the endoscope
Study NCT03055819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brow Lift
Description: Minimally Invasive Brow Lift
Study NCT02577848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: GLP-1 were taken daily for 7 days
Study NCT02577848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo were taken daily for 7 days
Study NCT00125619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Locomotor training
Description: This study compares two forms of Iocomotor training: 1) standard or manual - in which an individual is provided partial body weight support while walking on a treadmill with assistance of 1-3 therapists to move the legs and stabilize the trunk/pelvis and 2) robotic-guided - in which an exoskeleton robot (Lokomat) guides movement of the walking pattern. Partial body-weight support, treadmill walking and treadmill speed are consistent between the study arms.
Study NCT00125619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Locomotor training
Description: This study compares two forms of Iocomotor training: 1) standard or manual - in which an individual is provided partial body weight support while walking on a treadmill with assistance of 1-3 therapists to move the legs and stabilize the trunk/pelvis and 2) robotic-guided - in which an exoskeleton robot (Lokomat) guides movement of the walking pattern. Partial body-weight support, treadmill walking and treadmill speed are consistent between the study arms.
Study NCT00803335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal conjugated estrogen cream 0.5gm
Description: Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
Study NCT00803335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal conjugated estrogen cream 1.0gm
Description: Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
Study NCT02368691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
Study NCT02977468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merck 3475 Pembrolizumab
Description: Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of one to two cycles.
Study NCT02977468 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Description: Participants will receive Intraoperative radiation therapy (IORT) on the day of surgery.
Study NCT03296007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: A meditative practice involving paying attention to present moment experiences and focusing on breathing sensations.
Study NCT03296007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Description: A meditative practice involving paying attention to present moment experiences and focusing on breathing sensations.
Study NCT01641289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: >50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate \<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
Study NCT01641289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Paracetamol
Description: No paracetamol + Intravenous Artesunate~* If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen.
Study NCT02302625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
Study NCT02543697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adrenal venous sampling
Description: We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
Study NCT01372826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Group1
Description: Oral dose, 25 mg
Study NCT01372826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Group 2
Description: Oral dose, 25 mg
Study NCT01372826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Group3
Description: Oral dose, 25 mg
Study NCT01372826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118
Description: Oral dose, 25 mg
Study NCT02709798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenfu Injection
Study NCT02709798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Glucose Injection
Study NCT04950790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuxinin injection
Description: Shuxuening injection : 5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
Study NCT04950790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Basic treatment
Description: Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.
Study NCT04950790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.
Study NCT04950790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterilized water for injection，5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
Study NCT01838447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: The High Dose group is based on the age-specific UL. These doses were chosen to elevate 25OHD well above 50 nmol/L, while minimizing the risk of vitamin D toxicity (e.g. hypercalcemia, hypercalciuria)
Study NCT02326740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Study NCT02326740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02326740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab open-label
Study NCT02924181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartTouch Catheter
Description: Pulmonary vein (PV) isolation guided by CF information
Study NCT02569970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine 20 mg
Description: Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label.
Study NCT02569970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 20 mg
Description: Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label.
Study NCT04589377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: Training is focused on learning the principle of RAIN (recognize, accept, investigate, non-identify) in the context of physics learning.
Study NCT04557215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Study NCT04557215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Study NCT04557215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Study NCT04557215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine (NAC) is a clinically approved mucolytic agent.
Study NCT04557215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied.
Study NCT02464423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma-Informed Cognitive Behavioral Therapy enhanced (TI-CBTe)
Study NCT03028688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula oxygen
Description: Participants will receive high flow nasal cannula oxygen delivery during anesthesia. Participants will also have transcutaneous PCO2 measurements performed using a cutaneous electrode.
Study NCT01598064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GK#10
Description: GK#10, 1 pack tid
Study NCT01598064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 pack tid po
Study NCT00005777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal mechanical ventilation management
Description: Partial pressure of carbon dioxide (PCO2) target (>52 mm Hg)
Study NCT00005777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine mechanical ventilation management
Description: Partial pressure of carbon dioxide (PCO2) target \<48 mm Hg)
Study NCT00005777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.
Study NCT00005777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.
Study NCT00005777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The infants in the placebo groups received equal volumes of saline.
Study NCT00005777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The infants in the placebo groups received equal volumes of saline.
Study NCT00628212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin 10mg
Study NCT00628212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg
Study NCT00628212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin 40 mg
Study NCT00628212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02527733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Study NCT02527733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab and laser
Study NCT04099992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress reduction (MBSR)
Description: Mindfulness-based stress reduction (MBSR) is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session. MBSR teaches to become more aware of thoughts, feelings, and sensations, and to skillfully respond to stressors. Each of the sessions includes education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. Participants learn formal mindfulness practices (e.g., meditation, yoga, body scan, body scan) as well as informal such as awareness of breath, thoughts, or emotions, and mindfulness of daily activities. Participants will receive digital audio (MP3) downloads with guided MM practices, a home practice manual, and handouts with each week's assignments. Daily home practice will consist of 40-45 minutes of recorded practice. Participants will log their daily practice. If a participant misses a class, it is possible to make up the class on a different day.
Study NCT04099992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: Mindfulness-based stress reduction (MBSR) is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session. MBSR teaches to become more aware of thoughts, feelings, and sensations, and to skillfully respond to stressors. Each of the sessions includes education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. Participants learn formal mindfulness practices (e.g., meditation, yoga, body scan, body scan) as well as informal such as awareness of breath, thoughts, or emotions, and mindfulness of daily activities. Participants will receive digital audio (MP3) downloads with guided MM practices, a home practice manual, and handouts with each week's assignments. Daily home practice will consist of 40-45 minutes of recorded practice. Participants will log their daily practice. If a participant misses a class, it is possible to make up the class on a different day.
Study NCT04099992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health enhancement program (HEP)
Description: 8-week health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP matches MBSR in structure and content, and in parallel to MBSR, consists of music therapy, nutritional education, posture and balance movements, walking and stretching. Work with all practices with group discussion and exercises during an all-day spa day will match the all-day retreat in MBSR. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions. Participants will receive MP3 downloads on an MP3 player with recordings of health education topics, a home listening manual, and weekly handouts with each week's listening assignments. Participants will listen to these MP3 recordings daily for 40-45 minutes and log their daily adherence.
Study NCT04099992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health enhancement program (HEP)
Description: 8-week health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP matches MBSR in structure and content, and in parallel to MBSR, consists of music therapy, nutritional education, posture and balance movements, walking and stretching. Work with all practices with group discussion and exercises during an all-day spa day will match the all-day retreat in MBSR. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions. Participants will receive MP3 downloads on an MP3 player with recordings of health education topics, a home listening manual, and weekly handouts with each week's listening assignments. Participants will listen to these MP3 recordings daily for 40-45 minutes and log their daily adherence.